440 related articles for article (PubMed ID: 18723437)
1. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
[TBL] [Abstract][Full Text] [Related]
2. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
3. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
4. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
Daniels JM; Snijders D; de Graaff CS; Vlaspolder F; Jansen HM; Boersma WG
Am J Respir Crit Care Med; 2010 Jan; 181(2):150-7. PubMed ID: 19875685
[TBL] [Abstract][Full Text] [Related]
5. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
6. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD.
Powrie DJ; Wilkinson TM; Donaldson GC; Jones P; Scrine K; Viel K; Kesten S; Wedzicha JA
Eur Respir J; 2007 Sep; 30(3):472-8. PubMed ID: 17504798
[TBL] [Abstract][Full Text] [Related]
7. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
8. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
10. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease.
Donath E; Chaudhry A; Hernandez-Aya LF; Lit L
Respir Med; 2013 Sep; 107(9):1385-92. PubMed ID: 23768735
[TBL] [Abstract][Full Text] [Related]
12. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis.
Yao GY; Ma YL; Zhang MQ; Gao ZC
Respiration; 2013; 86(3):254-60. PubMed ID: 23817204
[TBL] [Abstract][Full Text] [Related]
13. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.
Soler N; Agustí C; Angrill J; Puig De la Bellacasa J; Torres A
Thorax; 2007 Jan; 62(1):29-35. PubMed ID: 16928715
[TBL] [Abstract][Full Text] [Related]
14. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
[TBL] [Abstract][Full Text] [Related]
15. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
16. [Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations].
Saldías PF; Díaz PO; Dreyse DJ; Gaggero BA; Sandoval AC; Lisboa BC
Rev Med Chil; 2012 Jan; 140(1):10-8. PubMed ID: 22552550
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease.
Llor C; Moragas A; Hernández S; Bayona C; Miravitlles M
Am J Respir Crit Care Med; 2012 Oct; 186(8):716-23. PubMed ID: 22923662
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease.
Sethi S; Wrona C; Eschberger K; Lobbins P; Cai X; Murphy TF
Am J Respir Crit Care Med; 2008 Mar; 177(5):491-7. PubMed ID: 18079493
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].
Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N;
Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]